Biotinylated Cynomolgus SOST/Sclerostin Protein
Catalog No: SOST-CB001
- Species
- Cynomolgus
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Cynomolgus SOST/Sclerostin Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Gln69-Tyr258 (accession: XP_005584428.2).
Product Details
- Molecular Aliases
- sclerostin; SOST; VBCHsclerosteosis; CDD; DAND6; SOST1; VBCH
- Protein Length
- Gln69-Tyr258
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 24.39 kDa. Due to glycosylation, the protein migrates to 32-38 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Supplied as 0.22 μm filtered solution in PBS, 200mM L-arginine (pH 7.4).
- State
- Liquid
- Storage Conditions
- Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Data Display
Biotinylated Cynomolgus SOST on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Immobilized Biotinylated Cynomolgus SOST, His Avi tag at 1μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Human LRP-6, mFc Tag with the EC50 of 37.6ng/ml determined by ELISA. (QC Test)
Immobilized Biotinylated Cynomolgus SOST, His Avi tag at 0.5μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-SOST Antibody, hFc Tag with the EC50 of 15.0ng/ml determined by ELISA.
Background
SOST, also known as sclerostin, is a member of the cerberus/DAN family, a group of secreted glycoproteins characterized by a cysteine-knot motif. SOST is negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation.
References
- Claire M N, Patton D, Hayes J S. Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges[J]. Journal of Osteoporosis, 2016, 2016:1-22.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.